-transparent.png){kind=logo}
A patient with regional enteritis and recurrent uric acid nephrolithiasis was treated with allopurinol. While on 600 mg of allopurinol daily, she began to pass many small, soft, yellow stones. Analysis of the stones by liquid chromatographic and gas chromatograph/mass spectrometric techniques revealed that their major constituent was oxypurinol, a metabolite of allopurinol. Metabolic studies of the patient indicated that increasing doses of allopurinol were associated with increases in xanthine and oxypurinol excretion, while uric acid excretion was not reduced. This case illustrates a complication of high-dose allopurinol therapy in the treatment of uric acid nephrolithiasis.
R M Stote, and
L H Smith, and
J W Dubb, and
T P Moyer, and
F Alexander, and
J L Roth
January 1978,
Deutsche medizinische Wochenschrift (1946),
R M Stote, and
L H Smith, and
J W Dubb, and
T P Moyer, and
F Alexander, and
J L Roth
January 1998,
Clinical and experimental dermatology,
R M Stote, and
L H Smith, and
J W Dubb, and
T P Moyer, and
F Alexander, and
J L Roth
September 1976,
Annals of internal medicine,
R M Stote, and
L H Smith, and
J W Dubb, and
T P Moyer, and
F Alexander, and
J L Roth
February 1993,
The Clinical investigator,
R M Stote, and
L H Smith, and
J W Dubb, and
T P Moyer, and
F Alexander, and
J L Roth
September 2011,
Clinical pharmacology and therapeutics,
R M Stote, and
L H Smith, and
J W Dubb, and
T P Moyer, and
F Alexander, and
J L Roth
October 1976,
Radiology,
R M Stote, and
L H Smith, and
J W Dubb, and
T P Moyer, and
F Alexander, and
J L Roth
March 1987,
FEBS letters,
R M Stote, and
L H Smith, and
J W Dubb, and
T P Moyer, and
F Alexander, and
J L Roth
June 1962,
Annals of internal medicine,
R M Stote, and
L H Smith, and
J W Dubb, and
T P Moyer, and
F Alexander, and
J L Roth
January 1989,
Advances in experimental medicine and biology,
R M Stote, and
L H Smith, and
J W Dubb, and
T P Moyer, and
F Alexander, and
J L Roth
April 1996,
British journal of clinical pharmacology,
